A double-blind, randomized, placebo-controlled study of the efficacy, safety/tolerability, and pharmacokinetic profile of UCB0942 in adult patients with highly drug-resistant focal epilepsy

Trial Profile

A double-blind, randomized, placebo-controlled study of the efficacy, safety/tolerability, and pharmacokinetic profile of UCB0942 in adult patients with highly drug-resistant focal epilepsy

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Aug 2017

At a glance

  • Drugs Padsevonil (Primary)
  • Indications Partial epilepsies
  • Focus Therapeutic Use
  • Sponsors UCB
  • Most Recent Events

    • 16 Aug 2017 Status changed from active, no longer recruiting to completed.
    • 16 Feb 2017 Planned End Date changed from 1 Dec 2016 to 1 Jun 2017.
    • 04 Nov 2016 Planned End Date changed from 1 Oct 2016 to 1 Dec 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top